Table 2 Vital sign and laboratory data on admission
Parameters | Development cohort | Validation cohort | Total cohort | |||
|---|---|---|---|---|---|---|
(N = 288) | (N = 244) | (N = 532) | ||||
Systolic blood pressure (mm Hg) | ||||||
≧ 90, n (%) | 212 | (73.6%) | 156 | (63.9%) | 368 | (69.2%) |
61–90 | 45 | (15.6%) | 45 | (18.4%) | 90 | (16.9%) |
Near cardiac arrest | 31 | (10.8 %) | 43 | (17.6%) | 74 | (13.9%) |
Body temperature (°C), median (IQR) | 30.7 (28.3–32.6) | 31.0 (28–32.7) | 30.8 (28.1–32.6) | |||
35–32, n (%) | 98 | (34.0%) | 77 | (31.6%) | 175 | (32.9%) |
32–28 | 124 | (43.1%) | 104 | (42.6%) | 228 | (42.9%) |
< 28 | 66 | (22.9%) | 63 | (25.8%) | 129 | (24.2%) |
Disturbance of consciousness | ||||||
Mild, n (%) | 110 | (38.2%) | 100 | (41.0%) | 210 | (39.5%) |
Moderate | 90 | (31.3%) | 70 | (28.7%) | 160 | (30.1%) |
Severe | 85 | (29.5%) | 68 | (27.9%) | 153 | (28.8%) |
Missing | 3 | (1.0%) | 6 | (2.5%) | 9 | (1.7%) |
pH, median (IQR) | 7.31 (7.25–7.37) | 7.31 (7.21–7.37) | 7.31 (7.23–7.37) | |||
> 7.35, n (%) | 85 | (29.5%) | 69 | (28.3%) | 154 | (28.9%) |
7.20–7.35 | 118 | (41.0%) | 98 | (40.2%) | 216 | (40.6%) |
< 7.20 | 42 | (14.6%) | 53 | (21.7%) | 95 | (17.9%) |
Missing | 43 | (14.9%) | 24 | (9.8%) | 67 | (12.6%) |
K+ (mmol/l), median (IQR) | 4.2 (3.6–4.7) | 4.0 (3.5–4.6) | 4.1 (3.6–4.7) | |||
< 3.5, n (%) | 59 | (20.5%) | 54 | (22.1%) | 113 | (21.2%) |
3.5–5.5 | 198 | (68.8%) | 155 | (63.5%) | 353 | (66.4%) |
> 5.5 | 30 | (10.4%) | 28 | (11.5%) | 58 | (10.9%) |
Missing | 1 | (0.3%) | 7 | (2.9%) | 8 | (1.5%) |
Albumin (g/dl), median (IQR) | 3.4 (2.9–4.0) | 3.5 (2.9–4.0) | 3.4 (2.9–4.0) | |||
> 3 | 163 | (56.6%) | 142 | (58.2%) | 305 | (57.3%) |
≤ 3 | 77 | (26.7%) | 61 | (25.0%) | 138 | (25.9%) |
Missing | 48 | (16.7%) | 41 | (16.8%) | 89 | (16.7%) |